Adamas Pharma (ADMS) Announces Launch of Follow-on Public Offering

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Adamas. Adamas intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

SVB Leerink and William Blair are acting as joint bookrunning managers for the offering. JMP Securities is acting as lead manager for the offering.

You May Also Be Interested In

• William Blair Starts Terawulf Inc. (WULF) at Outperform
• Forum Energy Technologies (FET) files mixed shelf
• William Blair Reiterates Outperform Rating on Workday (WDAY)